In a report published Thursday, Deutsche Bank analyst David Low downgraded the rating on ResMed RMD from Buy to Hold, but reiterated the $52.00 price target.
In the report, Deutsche Bank noted, “The Centers for Medicare & Medicaid Services (CMS) has issued a release to update among other things, details of the roll-out of Competitive Bidding (CB) round 3 and the phase in of special payment rules (i.e. ‘bundled funding'). The changes are set to take place on 1-Jan-15 and CMS is seeking comment on the proposal until 2-Sep-14. While there is the possibility the proposals will be knocked back, if implemented, the near term impact will likely be modest given bundled funding will only to be implemented in 12 areas. However, in the medium term this reform could materially slow mask sales growth if implemented widely (i.e. followed by private payors). We have cut our rating from Buy to Hold following this news and in recognition of the fact the shares are trading near our current price target and valuation. We will review our forecasts when additional detail on the reforms is released.”
ResMed closed on Wednesday at $50.50.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in